| scholarly article | Q13442814 |
| P50 | author | Stacy Robertson | Q85965009 |
| Ziad Mallat | Q45827826 | ||
| Christina A Bursill | Q62035675 | ||
| P2093 | author name string | Sanjay Patel | |
| David S Celermajer | |||
| Qiong Xia | |||
| Gonzalo J Martínez | |||
| Jennifer Barraclough | |||
| P2860 | cites work | Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study | Q84330186 |
| Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) | Q85063666 | ||
| IL-1 signaling in atherosclerosis: sibling rivalry | Q85947638 | ||
| A safe and easy technique to sample the coronary sinus--facilitating a closer look at cardiac disease | Q87622296 | ||
| Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis | Q27001736 | ||
| Gout-associated uric acid crystals activate the NALP3 inflammasome | Q28131797 | ||
| Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome | Q28586980 | ||
| NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals | Q29615704 | ||
| Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation | Q33644572 | ||
| Inflammation in atherosclerosis: from pathophysiology to practice | Q33709505 | ||
| The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. | Q34023691 | ||
| The immune system in atherosclerosis | Q34164644 | ||
| The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study | Q35059517 | ||
| Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. | Q35088128 | ||
| The role of interleukin-1 and the inflammasome in gout: implications for therapy | Q36956476 | ||
| Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis | Q37466366 | ||
| A clinical perspective of IL-1β as the gatekeeper of inflammation | Q37869439 | ||
| Multiple roles for neutrophils in atherosclerosis | Q37994653 | ||
| Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease | Q38137848 | ||
| Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial | Q38424365 | ||
| NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin | Q39110336 | ||
| Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction. | Q40314500 | ||
| Haplotypes of the caspase-1 gene, plasma caspase-1 levels, and cardiovascular risk | Q40315651 | ||
| Interleukin-6 and acute coronary syndrome. | Q40675496 | ||
| Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma | Q42162162 | ||
| High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study | Q43174058 | ||
| A randomized trial of colchicine for acute pericarditis | Q43494979 | ||
| Widespread coronary inflammation in unstable angina | Q44050104 | ||
| Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease | Q44207349 | ||
| Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina | Q45144844 | ||
| Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial | Q45369180 | ||
| Low-dose colchicine for secondary prevention of cardiovascular disease | Q46245044 | ||
| Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice | Q46507912 | ||
| Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). | Q46637686 | ||
| Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. | Q51531918 | ||
| Increased PTPN22 expression and defective CREB activation impair regulatory T-cell differentiation in non-ST-segment elevation acute coronary syndromes. | Q54281605 | ||
| Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. | Q54404047 | ||
| C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease | Q57605886 | ||
| Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability | Q58150063 | ||
| Interleukin-18/Interleukin-18 Binding Protein Signaling Modulates Atherosclerotic Lesion Development and Stability | Q58150092 | ||
| The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina | Q58230388 | ||
| 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention | Q58972787 | ||
| Lack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice | Q62735862 | ||
| Interleukin-1 beta in coronary arteries of patients with ischemic heart disease | Q71231733 | ||
| P433 | issue | 8 | |
| P921 | main subject | acute coronary syndrome | Q266018 |
| (S)-(−)-colchicine | Q326224 | ||
| P304 | page(s) | e002128 | |
| P577 | publication date | 2015-08-24 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome | |
| P478 | volume | 4 |
| Q52729993 | Ablation of Bax and Bak protects skeletal muscle against pressure-induced injury. |
| Q93012793 | Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition |
| Q95633714 | Clinical approach to the inflammatory etiology of cardiovascular diseases |
| Q38780826 | Colchicine in cardiovascular disease: an ancient drug with modern tricks |
| Q102374295 | Colchicine inhibits the prothrombotic effects of oxLDL in human endothelial cells |
| Q57063349 | Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1 |
| Q95933350 | Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial |
| Q91754413 | Diabetes Mellitus and Cardiovascular Disease |
| Q50860861 | Does long term colchicine prevent degradation of collagen fiber network in osteoarthritis? |
| Q90096848 | Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multimodality Imaging Study in an Animal Model |
| Q93232759 | Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel |
| Q95592165 | Exploratory Review of the Role of Statins, Colchicine, and Aspirin for the Prevention of Radiation-Associated Cardiovascular Disease and Mortality |
| Q26770209 | From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection |
| Q38851472 | Immune-mediated mechanisms of atherosclerosis and implications for the clinic |
| Q92256742 | Inflammation as a Therapeutic Target in Atherosclerosis |
| Q43228025 | Is There a Role for Colchicine in Acute Coronary Syndromes? |
| Q51617151 | Melatonin attenuated early brain injury induced by subarachnoid hemorrhage via regulating NLRP3 inflammasome and apoptosis signaling. |
| Q37589724 | Neutrophil-derived microparticles are released into the coronary circulation following percutaneous coronary intervention in acute coronary syndrome patients |
| Q92000753 | Novel Antiatherosclerotic Therapies |
| Q41675413 | Per os colchicine administration in cholesterol fed rabbits: Triglycerides lowering effects without affecting atherosclerosis progress |
| Q49603124 | Potential of anti-inflammatory agents for treatment of atherosclerosis |
| Q99633698 | Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein |
| Q61806016 | TRAIL-Expressing Monocyte/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis |
| Q64087475 | Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease |
| Q39206224 | Teaching an Old Dog New Tricks: Colchicine in Cardiovascular Medicine |
| Q91598451 | The GReek study in the Effects of Colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design |
| Q98291995 | The Role of MicroRNAs in Regulating Cytokines and Growth Factors in Coronary Artery Disease: The Ins and Outs |
| Q92128110 | The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 |
| Q38990014 | Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence |
| Q38985092 | What's Old is New Again - A review of the current evidence of colchicine in cardiovascular medicine |
Search more.